Brief: Shanghai Junshi Biosciences Gets Approval By HSA For Marketing Of Toripalimab
26/03/2025 13:49
March 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS: APPROVAL BY HSA FOR MARKETING OF TORIPALIMAB Further company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab